Recent experimental studies provide evidence for further promising therapeutic strategies, such as direct targeting of phosphate or FGFRs or magnesium supplementation to prevent toxicity of FGF23 and hyperphosphatemia in CKD patients. The gene discussed is FGF23; the disease is chronic kidney disease.